F.D.A. Nominee to Face Grilling Over Cutbacks and Policy Shifts
Published On Mar 6, 2025, 5:02 AM
Dr. Marty Makary is set to testify before the Senate health committee regarding his nomination as the FDA commissioner. He may face scrutiny over alleged staff reductions and shifts in the FDA's approach to vaccines. Notable for his contrarian views and criticism of existing medical protocols, Makary has previously garnered attention through his predictions on public health issues, particularly during the Covid pandemic. His relationship with the current health secretary further complicates perceptions of his stance on drug and health regulation.
Stock Forecasts
IBB
Positive
Dr. Makary's confirmation could indicate a shift in FDA policies, especially concerning vaccines and drug regulations. His contrarian approach may attract positive attention from some investors in biotech and health sectors looking for reform and innovation.
PFE
Negative
Conversely, his controversial ties and potential changes in FDA policy could lead sectors dependent on strict regulatory oversight, such as pharmaceuticals, to react negatively. Companies that rely on FDA approval for their products may experience volatility.
Related News
Small businesses seeing revenues rise, but tariff threats loom
Feb 26, 2025, 8:04 AM
A Bank of America Institute study found that small businesses' revenue grew at a faster pace than payments for the first time in three years, though tariffs could pose a challenge.
Treasury sets March 21 deadline for millions of businesses to report ownership information or risk fines of $10,000 or more
Feb 20, 2025, 11:10 AM
The Treasury set a March 21 deadline to report "beneficial ownership information" after a Texas court lifted a block on enforcement.
Trump says he will introduce 25% tariffs on autos, pharmaceuticals and chips
Feb 19, 2025, 3:45 PM
President Donald Trump is planning to impose 25% tariffs on imported automobiles as well as tariffs at a similar level on pharmaceutical imports and semiconductors.